Brands of Loratadine in Kenya

Cetin , Zest Pharma
Loratin Fast , Square Pharmaceuticals Ltd.
Loratol , Dafra Pharma Gmbh
Lorhistina , Cosmos Limited
Lorvic , Dawa Limited
Lorytec , Delorbis Pharmaceuticals Limited
Neoday , Neopharma L.L.C.
Pretin , Beximco Pharmaceuticals Ltd.
Soloratidin , Sakar Healthcare Ltd.

Loratadine in Kenya: Price, Uses, Brands
Loratadine Chemical Structure


Loratadine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.


This medicine is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children over the age of 2 years with a body weight more than 30 kg.


Adults and children over 12 years of age:

10 mg once daily (one tablet once daily). .

Paediatric population

Children 2 to 12 years of age are dosed by weight :

Body weight more than 30 kg: 10 mg once daily (one tablet once daily)

Body weight 30 kg or less: The 10 mg strength tablet is not appropriate in children with a body weight less than 30 kg. There are other formulations more suitable for children 2 to 12 years old with body weight 30 kg or less.

Efficacy and safety of this medicine in children under 2 years of age has not been established. No data are available.

Hepatic impairment

Patient with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine. An initial dose of 10 mg every other day is recommended for adults and children weighing more than 30 kg,

Renal impairment

No dosage adjustments are required in patients with renal insufficiency.


No dosage adjustments are required in the elderly.

Method of administration

Oral use. The tablet may be taken without regard to mealtime.


When administered concomitantly with alcohol, Loratadine have no potentiating effects as measured by psychomotor performance studies.

Potential interaction may occur with all known inhibitors of CYP3A4 or CYP2D6 resulting in elevated levels of loratadine , which may cause an increase in adverse events.

Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Paediatric population

Interaction studies have only been performed in adults.


System Organ ClassFrequencyAdverse Experience Term
Immune system disordersVery rareHypersensitivity reactions (including angioedema and anaphylaxis)
Nervous system disordersVery rareDizziness, convulsion
Cardiac disordersVery rareTachycardia, palpitation
Gastrointestinal disordersVery rareNausea, dry mouth, gastritis
Hepatobiliary disordersVery rareAbnormal hepatic function
Skin and subcutaneous tissue disordersVery rareRash, alopecia
General disorders and administration site conditionsVery rareFatigue
InvestigationsNot knownWeight increase


Paediatric population

In clinical trials in a paediatric population, children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue (1%).

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:

Loratadine In Kenya
Loratadine In Kenya
Loratadine In Kenya
Loratadine In Kenya
Loratadine In Kenya
Loratadine In Kenya
Loratadine In Kenya

Clinical | Pharmacokinetic data

Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: by mouth
Bioavailability: Not Available
Protein Binding: 97–99%
Metabolosim: liver (CYP2D6- and 3A4-mediated)
Onset of Action: Not Available
Elimination Half life: 8 hours, active metabolite desloratadine 27 hours
Excretion: 40% as conjugated metabolites into urine Similar amount into the feces

Legal Status | Dosage forms & Strengths

Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Tablets | Syrup

Drug Indentifiers:

CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.120.122

Drug Images

References/ Citation:

  • Ueda T, Arai S, Amoh Y, Katsuoka K (2011). “Kimura’s disease treated with suplatast tosilate and loratadine”. European Journal of Dermatology. 21 (6): 1020–1. doi:10.1684/ejd.2011.1539

What was the patient being treated for
%d bloggers like this: